Through nano-biopharmaceuticals we are witnessing new solutions being brought in to the field of medicine which was for years suffering from problems such as, drug delivery, precise targeting and effectiveness of treatment. These therapies utilize nanoscale materials like liposomes, nanoparticles and dendrimers which allows depot formulation, drug targeting and controlled drug release apart from improving the stability greatly hence increasing positive outcomes for hard diseases such as cancer, cardiovascular diseases, neurological diseases and last but not the least infectious diseases. Thus, new opportunities are accompanied by numerous threats: legislation and toxicity, manufacturing difficulties, and costs factors that may lead to restricted availability. Technological advancement is becoming more intense with the introduction of new techniques like CRISPR gene editing, immuno-nanomedicine and AI powered DOE opening door for personalized efficient treatments. More specifically, the foremost priorities include the therapeutic’s ethical implications, especially in the sphere of patient safety, and the therapeutic’s societal implications concerning fairness of access. Meeting these challenges will of course necessitate interdisciplinary efforts within pharmaceutical, technological, and regulatory forms, all within the context of an innovative and transparent process.